Administration of a conditionally replicative oncolytic canine adenovirus in normal dogs

Cancer Biotherapy and Radiopharmaceuticals

Volumn 21, Issue 6, 2006, Pages 601-606

  Smith, Bruce F ^a   Curiel, David T ^b   Ternovoi, Vladimir V ^b   Borovjagin, Anton V ^b   Baker, Henry J ^a   Cox, Nancy ^a   Siegal, Gene P ^c  

^a AUBURN UNIVERSITY   (United States)

^b and Clinical Center   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Adenovirus; Conditionally replicative; CRAd; Oncolytic; Osteosarcoma

Indexed keywords

ADENOVIRUS VECTOR; CONDITIONALLY REPLICATIVE ONCOLYTIC CANINE ADENOVIRUS; CYCLOPHOSPHAMIDE; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOENGINEERING; BONE TUMOR; CANCER SURVIVAL; CANINE ADENOVIRUS TYPE 2; CONTROLLED STUDY; DOG; DRUG SAFETY; HISTOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; NONHUMAN; OSTEOSARCOMA CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STRESS; TARGET ORGAN; VIRUS REPLICATION;

ADENOVIRUSES, CANINE; ANIMALS; BLOOD CELL COUNT; DOGS; HEALTH; INJECTIONS; VIRUS REPLICATION;

EID: 33846610915     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2006.21.601     Document Type: Article

References (12)

1. Dernell WS, Straw RC, Withrow SJ. Tumors of the skeletal system. In: Withrow SJ, MacEwen EG, eds., Small Animal Clinical Oncology. W.B. Saunders, Philadelphia, PA. 2001:378.
2. Heyman SJ, Diefenderer DL, Goldschmidt MJ, et al. Canine axial skeletal osteosarcoma: A retrospective study of 116 cases (1986-1989). Vet Surg 1992;21:304.
3. Ragland BD, Bell WC, Lopez-Ben RR, et al. Cytogenetics and molecular biology of osteosarcoma. Lab Invest 2002;82:365.
4. Levine RA, Fleischli MA. Inactivation of p53 and retinoblastoma family pathways in canine osteosarcoma cell lines. Vet Pathol 2000;37(1):54.
5. MacEwen EG, Pastor J, Kutzke J, et al. IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. J Cell Biochem 2004;92(1):77.
6. Flint AF, U'Ren L, Legare ME, et al. Overexpression of the erbB-2 proto-oncogene in canine osteosarcoma cell lines and tumors. Vet Pathol 2004;41(3):291.
7. Parato KA, Senger D, Forsyth PA, et al. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005;5(12):965.
8. Mathis JM, Stoff-Khalili MA, Curiel DT. Oncolytic adenoviruses-selective retargeting to tumor cells. Oncogene 2005;24(52):7775.
9. Hemminki A, Kanerva A, Kremer EJ, et al. A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol Ther 2003;7(2)163.
10. Plumb DC, ed. Plumb's Veterinary Drug Handbook, Stockholm, WI. Blackwell Publishing, Pharma Vet Inc., 2005.
11. Wang, M, Hemminki A, Siegal GP, et al. Adenoviruses with An RGD-4C modification Of the fiber knob elicit a neutralizing antibody response but continue to allow enhanced gene delivery. Gynecol Oncol 2005;96:341.
12. Veterinary Co-operative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CT-CAE) Following Chemotherapy or Biological Antineoplastic Therapy in Dogs and Cats, v1.0. Vet Compar Oncol 2004;2(4):194.